Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling Data and Patient Stratification Potential

Cumulus Oncology is actively seeking small molecule oncology assets that are at or near the IND-enabling stage. They aim to identify programs with strong translational relevance and a clear path to early clinical proof of concept.

 Approaches of interest:

• Well-characterized mechanism of action with potential for monotherapy or rational combinations
• Defined biomarkers to support patient selection
• Assets targeting multi-indication potential, particularly in inflammation-driven cancer pathways
• Small molecule assets are of highest interests

 Developmental stage of interest: 

• Opportunities from late preclinical research stage to Phase I stage are sought, particularly those demonstrating in vivo efficacy in solid tumor models.

The company is open to various collaboration opportunities, including licensing and research partnerships.

Please note: Faculty and researchers interested in applying for these opportunities based on technologies developed or disclosed at Vanderbilt must submit their proposals through the CTTC.